PATENT CLAIM ANALYSIS

Application Number: 15890290
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "134100"]

Abstract:
The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

Claim (Index 142):
A method of prophylactic treatment of hemophilia B in a human subject in need thereof, comprising intravenously administering to the subject multiple doses of about 25 IU/kg to about 50 IU/kg of a chimeric polypeptide comprising human Factor IX (FIX) and a FcRn binding partner (FcRn BP) at a dosing interval of 7 days between doses, wherein the FcRn BP is a human Fc, wherein the subject exhibits a baseline-subtracted plasma FIX activity trough level of at least 1 IU/dL, and wherein the baseline is the lowest measured plasma Factor IX level in the subject prior to administering the first dose of the chimeric polypeptide.

Metadata:
- Claim Count in Document: 75.0
- Percentile: 88.0
- Lexical Diversity: 2.13636
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14982934', '15043457', '13809276', '15043445', '15890284']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.807510341610868
- 35 USC 102 Novelty (BERT): 0.7237765577903215
- Combined Prediction Score: 0.7991369632288133
- Mean Citation Score: 888.62134
- Max Citation Score: 906.3905
- Similarity Product: 784.223632072717

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test